Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer
Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology by Classe et al, the addition of hyperthermic intraperitoneal chemotherapy to complete cytoreductive surgery appeared to significantly improve overall survival in patients with...
Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma
The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with the multikinase inhibitor anlotinib for the first-line treatment of advanced hepatocellular carcinoma...
Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor
The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma
In a Chinese single-center phase II trial reported in The Lancet Oncology, Lin et al found that the addition of perioperative toripalimab to concurrent chemoradiotherapy was active in patients with newly diagnosed high-risk stage III to IVa locoregionally advanced nasopharyngeal carcinoma with...
Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists
Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a...
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics.
Background
Prior research has revealed that firefighters have significantly...
FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.
The FDA also approved ...
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...
Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System
In a retrospective cohort study reported in The Lancet Oncology, Miller et al found that ICI treatment for cancer had similar efficacy and reduced toxicity in Black patients vs White patients in the U.S. Veterans Health Administration (VHA) system.
As stated by the investigators, “Black patients...
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monotherapy in immune checkpoint inhibitor treatment–naive patients with unresectable or metastatic...
Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment
An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...
What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults vs Older Adults?
Younger adults with colon cancer tend to be diagnosed at a later stage and have more aggressive types of tumors. Additionally, young patients living with colorectal cancer have long-term, adverse consequences on their lives, which are different from the impact the disease has on older adults,...
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology, which highlighted international collaborations to improve cancer therapy and outcomes across China and Asia.
...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer?
Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Suicide-Related Mortality in Male AYA Cancer Survivors
Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open.
Cancer is becoming more common among young patients, and cancer...
Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Neoadjuvant chemotherapy with vs without nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the International...
Performance of First-Line Chemotherapy Regimens in Unresectable Advanced or Metastatic Pancreatic Cancer
In a meta-analysis reported in The Lancet Oncology, Mastrantoni et al identified first-line chemotherapy regimens associated with better outcomes in patients with unresectable advanced or metastatic pancreatic cancer.
Study Details
The Bayesian network analysis included 79 randomized controlled ...
Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer
A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to ...
New Technique May Allow for Visualization of CAR T Cells Postinjection
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer.
Background
During...
AI Tool May Detect Cancer Gene Signatures in Biopsy Images
Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...
Cancer-Specific Mortality Trends Among U.S. Asian and Pacific Islander Populations
In a study reported in JAMA Network Open, Zhu et al found that cancer-specific mortality rates have decreased overall among U.S. Asian and Pacific Islander populations during recent years, although increases in cancer-specific mortality have been reported for some cancers.
Study Details
The...
Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity
In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity.
Study Details
In the...
Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Ahn et al found the combination of the PLK1 inhibitor onvansertib with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab showed activity in the second-line treatment of KRAS-mutant metastatic colorectal cancer.
...
Detecting Evidence of Lung Cancer in Exhaled Breath
Researchers may have developed ultrasensitive, nanoscale sensors that distinguished a key change in the chemistry of the breath of patients with lung cancer, according to a recent study published by Cheng et al in ACS Sensors.
Background
Individuals breathe out many gases, such as water vapor and ...
Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...
Neoadjuvant Chemoradiation Followed by Immunochemotherapy and Surgery May Improve Outcomes in Esophageal Cancer
A phase II clinical trial investigating the safety and efficacy of a triple combination of radiation, chemotherapy, and immunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma found that the therapy was effective in shrinking tumors, allowing for surgery, and ...
Immunotherapy Combination for Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...
Novel Liquid Biopsies and Cancer Detection
Researchers may have uncovered a novel strategy to detect cancer cells with a liquid biopsy that’s designed to be simpler, faster, and more informational than current methods, according to a recent study published by Walker et al in the nanoscience publication Small.
Study Methods and Results
In ...
Enfortumab Vedotin in Previously Treated Advanced Head and Neck Cancer
In a phase II trial (EV-202) reported in the Journal of Clinical Oncology, Swiecicki et al found that the antibody-drug conjugate enfortumab vedotin showed activity in heavily pretreated patients with recurrent or metastatic head and neck cancer (HNC).
Study Details
In the study, 46 patients who...
Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma
In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation.
Study Details
In the double-blind Alliance for Clinical Trials ...
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Recent advances in urothelial carcinoma treatments may offer a path to curative care for more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published by Milowsky in The New England Journal of Medicine. The findings indicated that...
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Just 50% of patients with early-onset cancers may report discussing fertility preservation options with their physicians prior to receiving oncology treatments, according to a recent study published by Keller et al in JAMA Network Open.
Background
“From an early-onset cancer diagnosis through to...
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostatectomy radiotherapy vs those who did not, with little difference observed among patients with early ...
FDA Approves Novel Companion Diagnostic Assay
Caris Life Sciences announced that the U.S. Food and Drug Administration (FDA) has approved MI Cancer Seek for use as a companion diagnostic assay to identify patients with cancer who may benefit from targeted therapies. Caris Life Sciences is a next-generation artificial intelligence techbio...
Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer
As reported in the Journal of Clinical Oncology by Jensen et al, the final analysis of the phase III Danish DBCG07-READ trial showed improved 10-year outcomes with the addition of epirubicin to docetaxel/cyclophosphamide adjuvant therapy in patients with TOP2A-normal breast cancer. The primary...
Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma
In a phase I study reported in The Lancet Oncology, Maruyama et al found that valemetostat—a novel dual inhibitor of EZH2 and EZH1—showed activity in patients with relapsed or refractory non-Hodgkin lymphoma.
Study Details
In the study, 90 patients from sites in Japan and the United States were...
Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers
Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine.
...
Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis
In a single-institution study reported in JAMA Oncology, Cinciripini et al found that patients with cancer who quit smoking after a smoking cessation intervention had improved overall survival after cancer diagnosis.
Study Details and Results
The study involved data on 4,526 patients who were...
SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer
A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response rates and 6-month progression-free survival, with an acceptable safety profile. The study (
Addition of Inavolisib to Palbociclib/Fulvestrant in PIK3CA-Mutated Advanced Breast Cancer
In a phase III trial (INAVO120) reported in The New England Journal of Medicine, Turner et al found that the addition of inavolisib to palbociclib/fulvestrant improved progression-free survival in the first-line treatment of patients with PIK3CA-mutated advanced breast cancer.
Inavolisib is an...
Study Finds Long-Term Risks Associated With Prostate Cancer Treatment and Highlights the Importance of Counseling Prior to Screening and Treatment
A large cohort study investigating the long-term treatment-related adverse effects and complications from prostate cancer treatment compared to an untreated control group has found that treatment was associated with higher rates of 10 potential complications in the 12 years after treatment. Given...
Study Finds In Situ Vaccination Using Tumor Treating Fields Plus Immune Checkpoint Inhibitors Extended Survival in Patients With Glioblastoma
A small study investigating tumor treating fields—an antimitotic electric fields therapy—in combination with pembrolizumab and temozolomide for the treatment of patients with glioblastoma was found to be a promising strategy, especially in patients with substantial residual tumor, according to the...
Breast Cancer Vaccine Could Be Preventive, Well Tolerated in High-Risk Patients
Researchers have uncovered insights into a novel investigational vaccine aimed at preventing triple-negative breast cancer. The findings by Rhoades et al were presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (Abstract 631) and simultaneously published in the Journal...
FDA Approves Novel T-Cell Immunotherapy for Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) approved the CD19-directed genetically modified autologous T-cell immunotherapy obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Efficacy and Safety
Efficacy was evaluated in...
New Insights Into Innate Resistance for Immunotherapies in Colorectal Cancer
Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer, with a recent study published by Arai et al in the Journal for ImmunoTherapy of Cancer. The findings indicated that the combination approach could...
Study Finds Long-Term Risks Associated With Prostate Cancer Treatment
A large cohort study investigated the long-term treatment-related adverse effects and complications from prostate cancer treatment compared with an untreated control group. The investigators found that treatment was associated with higher rates of 10 potential complications in the 12 years after...
Tanning Bed Access, Usage May Be Driving Higher Rates of Melanoma in New England
Investigators have uncovered a potential link between the availability and use of tanning beds and the rising rates of melanoma in New England, according to a recent study published by Wei et al in the Journal of Investigative Dermatology. The findings may provide critical insights to inform public ...
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers. The new guidelines followed the recent...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
In the phase III TULIP trial reported in the Journal of Clinical Oncology, Turner et al found that the third-generation HER2-targeted antibody-drug conjugate trastuzumab duocarmazine (T-Duo) improved progression-free survival vs physician's choice (PC) of treatment in patients with previously...
Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma
In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of nivolumab plus ipilimumab in patients with aggressive thyroid carcinoma.
Study Details
In the trial, 49 evaluable patients enrolled at Dana-Farber Cancer Institute between October 2017 and ...
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the BCR::ABL1 kinase inhibitor asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph-positive CML) in chronic phase. The FDA approval was granted on...
Outcomes With Brexucabtagene Autoleucel as Standard Therapy for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
In an analysis reported in the Journal of Clinical Oncology, Roloff et al found that use of brexucabtagene autoleucel as standard therapy in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) was associated with a high rate of measurable residual disease (MRD)-negative...
Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer
Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...
Risk of Ischemic Cardiotoxicity With Aromatase Inhibitors in Postmenopausal Patients With Early Breast Cancer
As reported in The Lancet Oncology by Lund et al, a Danish prospective cohort study showed no increased risk of ischemic cardiotoxicity with use vs no use of aromatase inhibitor treatment in postmenopausal patients with early-stage breast cancer.
Study Details
The study included identification of ...
Researchers May Have Uncovered Why Some AML Cells Resist Treatment
Researchers have provided new insights into acute myeloid leukemia (AML) and its resistance to venetoclax, according to a recent study published by Sango et al in Nature.
Although AML is a rare disease, approximately 20,800 U.S. patients will be diagnosed in 2024, according to the American Cancer...
Novel Antibody-Drug Conjugate Puxitatug Samrotecan May Demonstrate Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
The novel antibody-drug conjugate puxitatug samrotecan may have a manageable safety profile consistent with similar antibody-drug conjugates and demonstrated initial efficacy in patients with heavily pretreated advanced or metastatic solid tumors, according to new findings presented by...
How Hypoxia May Help Cancer Metastasize
Researchers have identified genes that breast cancer cells may use to survive in the bloodstream after escaping the low-oxygen regions of a tumor, according to a novel study published by Godet et al in Nature Communications. Each of the genes may serve as a potential therapeutic target to prevent...
Addition of Atezolizumab Plus Bevacizumab to Chemotherapy in Advanced Biliary Tract Cancer
In a phase II trial (IMbrave151) reported in the Journal of Clinical Oncology, Macarulla et al found that atezolizumab/bevacizumab plus chemotherapy produced a “modest” improvement in progression-free survival vs atezolizumab/placebo plus chemotherapy in first-line treatment of patients with...
Next-Generation Oral SERD in Postmenopausal Women With ER-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (SERENA-2) reported in The Lancet Oncology, Oliveira et al found that the next-generation oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival vs fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, HER2-negative...
Addition of Nivolumab to Tivozanib Following Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma
As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial has shown that immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib did not improve progression-free survival vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint...
Resection of Stage I to III Thymic Tumors in High-Volume U.S. Centers
In a study reported in a research letter in JAMA Surgery, Sakowitz et al found that R0 resection was more commonly achieved in patients with stage I to III thymic tumors who received surgery at high-volume centers (HVCs) for thymectomy in the United States.
Study Details and Results
The study...
Risk of Second Primary Cancers After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
In an English study reported in the Journal of Clinical Oncology, Allen et al found that patients with breast cancer harboring BRCA1/BRCA2 pathogenic variants were at high risk of second primary cancers.
Study Details and Results
The study involved follow-up of 25,811 females and 480 males...
$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities
Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...
Case Study Shows Striking Improvements in Patient Treated for Metastatic Prostate Cancer With Antibody-Drug Conjugate
A landmark case report suggested a potential breakthrough in the treatment of an aggressive type of prostate cancer, according to a recent study published by Lap et al in the Annals of Internal Medicine.
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was approved by the U.S....
Trends in Use of Primary Cytoreductive Surgery and Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer
In a study reported in a research letter in JAMA Network Open, Bercow et al found reduced use of primary cytoreductive surgery (PCS) and increased use of neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) in patients with advanced epithelial ovarian cancer during...
Jennifer Bickel, MD, Named MD Anderson Vice President and Chief Wellness Officer
The University of Texas MD Anderson Cancer Center recently announced the selection of Jennifer Bickel, MD, as the institution’s inaugural Vice President and Chief Wellness Officer (CWO). She will assume this role on January 6, 2025.
Working closely with the Shibu Varghese, MA, Senior Vice...
Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings provided insights that could help advance...
Novel Method for Liquid Biopsies May Streamline Cancer Detection
Researchers have discovered a novel strategy to detect cancer cells with a liquid biopsy designed to be simpler, quicker, and more informational compared with current methods, according to a recent study published by Walker et al in Small.
Background
Current methods for detecting cancer cells may ...
Prediction of Fracture Risk in Patients With Cancer
In a Canadian population–based cohort study reported in JAMA Oncology, Ye et al found that patients with cancer were at increased risk of fracture compared with individuals without cancer. In addition, a Fracture Risk Assessment Tool (FRAX) provided accurate prediction of this increased risk.
As...
Valemetostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (VALENTINE-PTCL01) reported in The Lancet Oncology, Zinzani et al found that valemetostat—a novel dual inhibitor of EZH1 and EZH2—was active in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Study Details
In the trial, 133 patients with relapsed or...
Quantifying the Benefit of Smoking Cessation Within 6 Months of a Cancer Diagnosis
Quitting smoking within 6 months of receiving a cancer diagnosis could add an average of 2 years to a patient’s life, according to a recent study published by Cinciripini et al in JAMA Oncology. The findings demonstrated a broad survival benefit of using evidence-based smoking cessation to help...
NCCN Harmonized Guidelines for Sub-Saharan Africa: Experts Convene in Ghana to Update Cancer Treatment Guidelines
An international team of oncology experts gathered in Accra, Ghana, for a series of meetings to update cancer treatment recommendations in the National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa.
Background
The NCCN Harmonized Guidelines offer color-coded...
Inotuzumab Ozogamicin With Low-Intensity Chemotherapy in Older Patients With CD22-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL
In a phase II trial (EWALL-INO) reported in the Journal of Clinical Oncology, Chevallier et al found that inotuzumab ozogamicin combined with low-dose chemotherapy was active in the first-line treatment of older patients with newly diagnosed CD22-positive Philadelphia chromosome–negative B-cell...
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In a phase IIa study (DisTinGuish) reported in the Journal of Clinical Oncology, Klempner et al found that use of the DKK1-neutralizing antibody DKN-01 in combination with tislelizumab and chemotherapy showed activity in the first-line treatment of patients with advanced gastric or gastroesophageal ...
CDK4/6 Inhibition in Peritoneal Mucinous Carcinomatosis With GNAS Mutation
In a single-institution study reported in the Journal of Clinical Oncology, Weitz et al found that the CDK4/6 inhibitor palbociclib was active as a novel treatment in patients with peritoneal mucinous carcinomatosis with GNAS mutation.
As stated by the investigators: “Mucinous neoplasms of the...
Using AI to Measure Prostate Cancer Lesions Could Aid Diagnosis and Treatment
Researchers have trained and validated an artificial intelligence (AI) model based on magnetic resonance imaging (MRI) scans to develop a consistent method of estimating prostate cancer lesion size, according to a recent study published by Yang et al in Radiology. The findings could aid physicians...
Weighing Blood-Based vs Standard Colorectal Cancer Screening Options
Because colonoscopies and more established stool-based tests are more effective at detecting early cancers and precancerous polyps compared with emerging blood-based tests, their long-term impact is projected to be substantially greater than that of blood-based tests, according to a recent study...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported in the Journal of Clinical Oncology by Galsky et al, extended follow-up of the phase III CheckMate 274 trial supported the efficacy of adjuvant nivolumab in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical resection.
Study Details
In the...
Lung Cancer Screening Model May Remove Barriers for Vulnerable Patients Residing in Central Texas
A new lung cancer screening initiative may help to overcome barriers to care among low-income, uninsured, and minority patients residing in Central Texas, according to a recent study published by Pignone et al in the American Journal of Preventive Medicine. The findings represented a critical step...
New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
Using computational tools, researchers have developed a novel method to assess which patients with metastatic triple-negative breast cancer may benefit from immunotherapy, according to a recent study published by Arulraj et al in the Proceedings of the National Academy of Sciences (PNAS).
...
Addition of Lenvatinib to Ifosfamide/Etoposide in Children and Young Adults With Relapsed Osteosarcoma
In a phase II study (OLIE) reported in JAMA Oncology, Gaspar et al found that the addition of lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma.
Study Details
In the global open-label...
Addition of Cadonilimab to Platinum-Based Chemotherapy With or Without Bevacizumab in Cervical Cancer
In interim analyses of a Chinese phase III trial (COMPASSION-16) reported in The Lancet, Wu et al found that the addition of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, to platinum-based chemotherapy with or without bevacizumab significantly improved progression-free and overall...
Distant Recurrence Risk Among Women With Early Breast Cancer Enrolled in Clinical Trials Between 1990 and 2009: EBCTCG Analysis
In an analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported in The Lancet, Hills et al found that risk of distant recurrence declined over time among women with early breast cancer enrolled in clinical trials between 1990 and 2009.
Study Details
The pooled analysis...
Association Between Pathologic Response and Relapse-Free Survival With Neoadjuvant Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
In an analysis reported in The Lancet Oncology, D’Alessio et al found that major pathologic response and complete pathologic response to neoadjuvant immune checkpoint inhibitor therapy was associated with improved relapse-free survival in patients with hepatocellular carcinoma.
Study Details
The...
Medicaid Expansion May Improve Cancer Care, Survival Among Patients With Hormone Receptor–Negative, HER2-Positive Breast Cancer
Patients with newly diagnosed hormone receptor–negative, HER2-positive breast cancer were more likely to receive timely, guideline-concordant treatment and experience longer survival in states participating in Medicaid expansion under the Affordable Care Act, according to a recent study published...
New Marker for Immunotherapy Response in Hepatocellular Carcinoma
A newly described stage of lymph node–like structures, known as tertiary lymphoid structures, identified in hepatic tumors following presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a recent study published by Shu et al in Nature...
ECOG-ACRIN Cancer Research Group, Caris Life Sciences Partner to Learn More From TAILORx Trial
The ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a new multiyear research collaboration that will begin with the interrogation of the TAILORx trial.
Background
Breast cancer remains the most common cancer type in the United States, with approximately 310,720 new cases per...
Early Results Show Novel Agent Has Clinical Activity in FGFR3-Driven Advanced Bladder Cancer
In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Addition of Induction Chemotherapy to Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer.
Study Details
In the open-label trial,...
Immunotherapy Plus Targeted Therapy for Anaplastic Thyroid Carcinoma
Researchers have demonstrated that anti–PD-L1 immunotherapy combined with mutation-directed targeted therapy may improve overall survival in patients with anaplastic thyroid carcinoma, according to a recent study published by Cabanillas et al in JAMA Oncology.
Background
Anaplastic thyroid...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting.
Background
Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science, ...
SBRT vs Conventional Radiotherapy for Localized Prostate Cancer
As reported in The New England Journal of Medicine by van As et al, the phase III PACE-B trial has shown noninferiority of stereotactic body radiotherapy (SBRT) vs conventionally fractionated radiotherapy in biochemical or clinical failure in patients with low- to intermediate-risk localized...
Mutations and DNA Structures May Drive Urothelial Carcinoma
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
Impact of Hormonal Contraception on Breast Cancer Risk in BRCA1 and BRCA2 Germline Mutation Carriers
In a study reported in the Journal of Clinical Oncology, Phillips et al found that carriers of BRCA1—but not BRCA2—germline mutations who used hormonal contraception were at increased risk for developing breast cancer.
Study Details
The investigators used pooled data from four prospective cohort...
Risk of Subsequent Neoplasms in Survivors of Childhood Neuroblastoma
In a Dutch study reported in the Journal of Clinical Oncology, Westerveld et al identified long-term risks of subsequent neoplasms in 5-year survivors of childhood neuroblastoma.
Study Details
The study included data from 563 survivors in the Dutch Childhood Cancer Survivor Study–LATER cohort...
Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC).
Study Details
In the multicenter trial, 46...
New $3.3 Million NCI Grant May Facilitate Development of More Accurate, Comfortable Breast Cancer Screening Technology
The University of Arizona Health Sciences announced that it has received a $3.3 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to continue testing a novel imaging method for breast cancer detection that could provide an alternative to the mammogram.
...
MRI May Help Prevent Unnecessary Surgery in Patients With Rectal Cancer
Magnetic resonance imaging (MRI) may help patients with rectal cancer avoid invasive surgery and its potentially lifelong side effects, according to a recent study published by Williams et al in Radiology.
Background
“After undergoing chemotherapy and radiation for rectal cancer, patients are...
